Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;78(4):429-37.
doi: 10.1007/BF00688180.

Immunodetection of the amyloid P component in Alzheimer's disease

Affiliations

Immunodetection of the amyloid P component in Alzheimer's disease

T Duong et al. Acta Neuropathol. 1989.

Abstract

Amyloid P component (AP), a plasma constituent normally not found in brain parenchyma, has been immunohistochemically determined in brains from patients with Alzheimer's disease (AD). Tissue came from 11 clinically diagnosed and neuropathologically verified AD patients and from 6 normal aged controls. Positive labeling for AP was observed in amyloidotic blood vessels, senile plaques (SP) and neurofibrillary tangles (NFT). The immunoreactivity was specific for these AD-associated lesions and clearly revealed their morphological appearance. Affected blood vessels appeared to be mainly of the arteriolar type and were labeled abluminally in short segments. SP constituents such as amyloid fibrils, amyloid core and degenerative axonal and dendritic processes were positive for AP antiserum; the morphology and distribution of immunoreactive SP corresponded to previous descriptions. Labeling of NFT revealed the morphology of paired helical and straight filaments. In all cerebral areas studied, tangle-bearing neurons were immunoreactive to AP antiserum, suggesting that AP is involved in early cellular development of NFT. Given the large molecular weight of AP (about 220,000), these results point to a potential impairment of the blood-brain barrier in AD. Since AP is always present in systemic amyloidosis, its detection in cerebral amyloidosis associated with AD may suggest mechanisms common to the two disorders.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 1977 Feb;74(2):739-43 - PubMed
    1. Lab Invest. 1988 Apr;58(4):454-8 - PubMed
    1. Arch Neurol. 1985 Nov;42(11):1097-105 - PubMed
    1. J Biol Chem. 1985 Oct 25;260(24):13384-8 - PubMed
    1. Acta Neuropathol. 1986;70(3-4):249-56 - PubMed

Substances

LinkOut - more resources